DelveInsight Business Research LLP

DelveInsight’s ‘Spasticity – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of spasticity historical and forecasted epidemiology as well as the spasticity market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Spasticity Overview

Spasticity is a condition in which there is an abnormal increase in muscle tone or muscle stiffness, which might interfere with movement and speech or be associated with discomfort or pain. Spasticity may be associated with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders and often interferes with daily activities.

Spasticity Epidemiology Insights 

• In 2021, the total cases of spasticity were ~7,871,000 in the 7MM which is expected to increase by 2032.

• The United States, in 2021, accounted for the highest number of cases of spasticity (~4,756,000 cases). These cases are expected to increase by the year 2032.

• In 2021, Japan accounted for ~823,000 cases of spasticity, which was approximately 10% of the total spasticity cases in 7MM.

• The total number of mild, moderate, and severe spasticity cases in the 7MM was ~1,504,000; ~2,424,000; and ~1,582,000 in 2021.

• In 2021, the total number of spasticity cases due to cerebral palsy, multiple sclerosis, post-stroke, traumatic brain injury, and spinal cord injury were ~533,000; ~499,000; ~689,000; ~472,000; and ~98,000 respectively in the EU5.

Click here to learn more about the Spasticity Market Landscape

The Report Covers the Spasticity Epidemiology Segmented by:

• Spasticity prevalent cases 

• Spasticity diagnosed cases 

• Spasticity treatment cases 

• Spasticity incident cases 

Spasticity Market Outlook

Spasticity affects a patient’s independence in activities of daily living such as hygiene, dressing, self-comfort, ambulation, and sleep. Later it may lead to significant pain, contractures, joint subluxations or dislocations, peripheral neuropathy, and pressure ulcers. Therefore, treating this condition is imperative to improve the quality of life and minimize medical complications. Conversely, spasticity can help patients transfer, stand, ambulate, and maintain muscle bulk.

Various treatments are available for controlling spasticity; nonmedical treatments, including physical, occupational, and complementary and alternative medicine, are effective adjuncts to mainstream oral agents and interventional therapies. While each therapy is efficacious in treating spasticity, the treatments also come with adverse effects. In general, oral agents are more inexpensive in the short term and easier to use, but they have unwanted systemic effects, which can outweigh the potential benefits they may provide. At the same time, these systemic drugs may be better for patients with generalized spasticity.

On the other hand, interventional therapies pose the problem of procedural errors, difficulty finding a trained provider to perform the procedure, and further complications. However, it may provide greater control of spasticity with fewer systemic side effects if patients are compliant and can tolerate the procedures. Although there are effective treatment options for spasticity, there is currently no cure.

Key Companies Working in the Spasticity Market

• Ipsen Biopharmaceuticals, Inc

• RVL Pharmaceuticals 

• Merz Pharmaceuticals

• Allergan, Inc

• Jazz Pharmaceuticals

• Metacel Pharmaceuticals

And many others 

Spasticity Therapies Covered and Analyzed in the Report:

• Arbaclofen ER

•  IPN10200

• MYOBLOC

• Botulinum toxin 

• SPARC0921

• Hyaluronidase

And many others 

Learn more about the Key Companies and Emerging Therapies in the Spasticity Market

Table of Contents 

1. Key Insights 

2. Spasticity  Introduction 

3. Executive Summary of Spasticity    –     

4. Disease Background and Overview

5. Epidemiology and patient population

6. Spasticity Emerging Therapies

7. Spasticity  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Spasticity Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services